Late-Stage COVID-19 Treatment Study 'Paused'

Indiana-based Eli Lilly announced on October 13, 2020, that the late-stage clinical trial of its COVID-19 antibody treatment LY-CoV555 has been paused because of a safety concern. “Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” Lilly spokeswoman Molly McCully said in an emailed statement to Reuters. 

LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19.